Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab for Angiosarcoma
NCT05026736Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2021
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in angiosarcoma, sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2021; status: terminated.
02
Drugs
sintilimab
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on NCT05026736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05026736.